Christopher Murphy is Vice President and General Manager of Viral Vector Services North America in Thermo Fisher Scientific’s Pharma Services Group. Prior to joining Thermo Fisher, Chris served as chief operating officer for Brammer Bio, a leading viral vector/gene therapy CDMO. Chris has more than 30 years of experience in biopharmaceutical manufacturing, process development, plant operations, and quality system implementation. Prior to joining Brammer Bio, Chris served as general manager for the Sanofi-Genzyme Allston Landing site overseeing operations and leading an integrated remediation program associated with the consent decree. Chris has led gene therapy operations and recombinant protein manufacturing at Genzyme and Bioreliance and he began his career in viral vaccine development at American Cyanamid/Wyeth (now Pfizer) in Pearl River, NY. He has an M.Sc. in biochemistry at New York Medical College, and his B.Sc. in biology at Rutgers University.